会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • TRIFUNCTIONAL ANTITHROMBIN AND ANTIPLATELET PEPTIDES
    • 功能性抗血栓素和抗血小板肽
    • WO1994029349A1
    • 1994-12-22
    • PCT/US1994005355
    • 1994-05-13
    • MERRELL DOW PHARMACEUTICALS INC.BROERSMA, Robert, J., Jr.OWEN, Thomas, J.KRSTENANSKY, John, L.
    • MERRELL DOW PHARMACEUTICALS INC.
    • C07K15/00
    • C07K14/815A61K38/00C07K14/75
    • Compounds of the formula: X-A-B-C-Y wherein X is an amino terminal residue selected from hydrogen, one or two alkyl groups of from 1 to 6 carbon atoms, one or two acyl groups of from 2 to 10 carbon atoms, carbobenzyloxy, H2NC(=NH)-, or a t-butyloxy carbonyl group; A is a peptide analog of the formula: A1-A2-A3 wherein A1 is (D)Phe, (D)Phg, (D)1-Tiq, (D)3-Tiq, N-Me- (D)Phe, (D)Cha, (D)Chg, (D)Nag, or (D)Thg; A2 is Pro, Pip, or Azt; A3 is Arg, Lys, Orn, or hArg; B is a peptide analog of formulae (3) or (4) wherein B1 is Gly, Ala, (D)Ala, Val, (D)Val, or Gly-Gly; B2 is Gly, Gly-Gly, Gly-Gly-Gly, Gly-Gly-Gly-Gly or any (D) amino acid; B2' is Arg-Ile-Pro or Lys-Ile-Pro; B3 is Arg, hArg, N-Me-Arg or Lys; B4 is Nle, Phe, Met or Cha; C is a peptide analog of the formula: Asp-C1-C2-C3-C4-C5-C6-C7-C8-C9 wherein C1 is Phe, pC1Phe, pNO2Phe, Tha, Npa, Tyr or Trp; C2 is Glu or Asp; C3 is any amino acid; C4 is Ile, Val, Leu or Phe; C5 is Pro, Hyp, Sar, NMePgl or D-Ala; C6 is any amino acid; C7 is any amino acid; C8 is Tyr, Glu, Pro, Ala-Cha, Tyr-Cha, Tyr-Leu and Ala-Tyr; C9 is a bond or is Glu, (D)Glu, Gln, Pro, Leu-Gln, Asp-Glu, or Leu-Pro; and Y is a carboxy terminal residue selected from OH, C1-C6 alkoxy, amino, mono- or di-(C1-C4) alkyl substituted amino, or benzylamino; or pharmaceutically acceptable salts thereof are useful anticoagulant agents. This invention also relates to the use of the above compounds in treating acute postangioplasty occlusion, extracorporeal circulation-induced cytopenia, developing myocardial infarction, and post fibrinolytic therapy occlusion.
    • 式XABCY的化合物,其中X是选自氢,一个或两个1-6个碳原子的一个或两个烷基,一个或两个2-10个碳原子的酰基,苄氧羰基,H 2 NC(= NH) - 或叔丁氧基羰基; A是下式的肽类似物:A1-A2-A3,其中A1是(D)Phe,(D)Phg,(D)1-Tiq,(D)3-Tiq,N-Me-(D) (D)Cha,(D)Chg,(D)Nag或(D)Thg; A2是Pro,Pip或Azt; A3是Arg,Lys,Orn或hArg; B是式(3)或(4)的肽类似物,其中B1是Gly,Ala,(D)Ala,Val,(D)Val或Gly-Gly; B2是Gly,Gly-Gly,Gly-Gly-Gly,Gly-Gly-Gly-Gly或任何(D)氨基酸; B2'是Arg-Ile-Pro或Lys-Ile-Pro; B3是Arg,hArg,N-Me-Arg或Lys; B4为Nle,Phe,Met或Cha; C是下式的肽类似物:Asp-C1-C2-C3-C4-C5-C6-C7-C8-C9,其中C1是Phe,pC1Phe,pNO2Phe,Tha,Npa,Tyr或Trp; C2是Glu或Asp; C3是任何氨基酸; C4是Ile,Val,Leu或Phe; C5是Pro,Hyp,Sar,NMePgl或D-Ala; C6是任何氨基酸; C7是任何氨基酸; C8是Tyr,Glu,Pro,Ala-Cha,Tyr-Cha,Tyr-Leu和Ala-Tyr; C9是Glu或Glu,(D)Glu,Gln,Pro,Leu-Gln,Asp-Glu或Leu-Pro; 和Y是选自OH,C 1 -C 6烷氧基,氨基,单 - 或二 - (C 1 -C 4)烷基取代的氨基或苄基氨基的羧基末端残基; 或其药学上可接受的盐是有用的抗凝血剂。 本发明还涉及上述化合物在治疗急性血管成形术闭塞,体外循环诱导的血细胞减少,发展中的心肌梗死和纤维蛋白溶解治疗闭塞中的用途。